Edwards Lifesciences Corporation (NYSE:EW) Given Average Rating of “Moderate Buy” by Brokerages

Edwards Lifesciences Corporation (NYSE:EW) has earned a consensus rating of “Moderate Buy” from the twenty-eight brokerages that are currently covering the company, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $95.6522.

Several analysts recently weighed in on EW shares. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Wells Fargo & Company raised their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Robert W. Baird raised their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th.

Edwards Lifesciences Stock Up 0.5%

Shares of NYSE:EW opened at $86.41 on Friday. The firm’s 50 day moving average price is $81.73 and its 200 day moving average price is $83.01. The stock has a market cap of $49.76 billion, a price-to-earnings ratio of 45.96, a price-to-earnings-growth ratio of 2.17 and a beta of 0.87. Edwards Lifesciences has a fifty-two week low of $72.30 and a fifty-two week high of $88.28. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts predict that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares in the company, valued at $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 106,397 shares of company stock worth $8,848,664 over the last three months. Insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds have recently modified their holdings of EW. Norges Bank purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares during the last quarter. Viking Global Investors LP purchased a new position in shares of Edwards Lifesciences during the third quarter worth approximately $238,688,000. Marshall Wace LLP grew its position in shares of Edwards Lifesciences by 66.1% during the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after acquiring an additional 2,359,128 shares during the last quarter. Finally, Jennison Associates LLC grew its position in shares of Edwards Lifesciences by 19.6% during the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after acquiring an additional 2,287,783 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.